An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies
- PMID: 26794401
- PMCID: PMC7482365
- DOI: 10.1136/jmedgenet-2015-103446
An interstitial deletion within 9p21.3 and extending beyond CDKN2A predisposes to melanoma, neural system tumours and possible haematological malignancies
Abstract
Familial atypical multiple mole melanoma syndrome (FAMMM) is characterised by dysplastic naevi, malignant melanoma and pancreatic cancer. Given that large deletions involving CDKN2A (cyclin-dependent kinase inhibitor 2A) account for only 2% of cases, we describe a family that highlights the co-occurrence of both melanoma and neural system tumours to aid clinical recognition and propose a management strategy. A patient with multiple neurofibromas was referred with a provisional diagnosis of neurofibromatosis type 1 (NF1). Prior molecular testing, though, had failed to identify an NF1 mutation by sequencing and multiplex ligation-dependent probe amplification. His family history was significant for multiple in situ/malignant melanomas at young ages and several different cancers reminiscent of an underlying syndrome. A search of the Familial Cancer Database, FaCD Online, highlighted several families with cutaneous melanoma and nervous system tumours who were subsequently identified to have large deletions spanning CDKN2A Although sequencing of CDKN2A and TP53 failed to identify a mutation, a heterozygous CDKN2A deletion was identified by targeted array comparative genomic hybridisation (CGH). Whole-genome oligonucleotide array CGH and SNP analysis identified an interstitial deletion of at least 1.5 Mb within 9p21.3 and spanning approximately 25 genes. Identification of the underlying molecular abnormality permits predictive testing for at-risk relatives. Given the young cancer diagnoses, a surveillance regimen was developed and a clinical team organised for ongoing management so that genetic testing could be offered to both adults and minor children. Surveillance recommendations addressed cancer risks associated with FAMMM, and other cancers exhibited by this family with a large contiguous gene deletion.
Keywords: Cancer: CNS; Cancer: dermatological; Clinical genetics; Genetic screening/counselling; Molecular genetics.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Conflict of interest statement
Competing interests: None declared.
Figures
Comment in
-
A germline deletion of 9p21.3 presenting as familial melanoma, astrocytoma and breast cancer: clinical and genetic counselling challenges.J Med Genet. 2017 Oct;54(10):682-684. doi: 10.1136/jmedgenet-2017-104690. Epub 2017 Jul 28. J Med Genet. 2017. PMID: 28754699 No abstract available.
Similar articles
-
A large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma.BMC Med Genet. 2014 May 17;15:59. doi: 10.1186/1471-2350-15-59. BMC Med Genet. 2014. PMID: 24884915 Free PMC article.
-
CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature.Br J Dermatol. 2016 Oct;175(4):785-9. doi: 10.1111/bjd.14485. Epub 2016 Jun 8. Br J Dermatol. 2016. PMID: 26876133 Review.
-
Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.Melanoma Res. 2017 Apr;27(2):97-103. doi: 10.1097/CMR.0000000000000324. Melanoma Res. 2017. PMID: 28060055
-
Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.Cancer. 2002 Jan 1;94(1):84-96. doi: 10.1002/cncr.10159. Cancer. 2002. PMID: 11815963
-
[From gene to disease; from p16 to melanoma].Ned Tijdschr Geneeskd. 2000 Oct 28;144(44):2100-2. Ned Tijdschr Geneeskd. 2000. PMID: 11103670 Review. Dutch.
Cited by
-
Cell fusion upregulates PD-L1 expression for evasion from immunosurveillance.Cancer Gene Ther. 2024 Jan;31(1):158-173. doi: 10.1038/s41417-023-00693-0. Epub 2023 Nov 21. Cancer Gene Ther. 2024. PMID: 37990063
-
A CRISPR-del-based pipeline for complete gene knockout in human diploid cells.J Cell Sci. 2023 Mar 15;136(6):jcs260000. doi: 10.1242/jcs.260000. Epub 2023 Mar 7. J Cell Sci. 2023. PMID: 36762651 Free PMC article.
-
Impact of Transcript (p16/p14ARF) Alteration on Cancer Risk in CDKN2A Germline Pathogenic Variant Carriers.JNCI Cancer Spectr. 2022 Nov 1;6(6):pkac074. doi: 10.1093/jncics/pkac074. JNCI Cancer Spectr. 2022. PMID: 36269225 Free PMC article.
-
9p21.3 Microdeletion involving CDKN2A/2B in a young patient with multiple primary cancers and review of the literature.Cold Spring Harb Mol Case Stud. 2022 Jun 22;8(4):a006164. doi: 10.1101/mcs.a006164. Print 2022 Jun. Cold Spring Harb Mol Case Stud. 2022. PMID: 35422439 Free PMC article. Review.
-
Nervous system (NS) Tumors in Cancer Predisposition Syndromes.Neurotherapeutics. 2022 Oct;19(6):1752-1771. doi: 10.1007/s13311-022-01277-w. Epub 2022 Sep 2. Neurotherapeutics. 2022. PMID: 36056180 Free PMC article. Review.
References
-
- Ghiorzo P, Gargiulo S, Pastorino L, Nasti S, Cusano R, Bruno W, Gliori S, Sertoli MR, Burroni A, Savarino V, Gensini F, Sestini R, Queirolo P, Goldstein AM, Bianchi Scarrà G. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. Hum Mol Genet 2006;15(18):2682–9. - PubMed
-
- Hayward NK. Genetics of melanoma predisposition. Oncogene 2003;22:3053–62. - PubMed
-
- Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril M- F, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, MacKie RM, Magnusson V, Mann GJ, Niendorf K, Bishop JN, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E, The Lund Melanoma Study Group, and the Melanoma Genetics Consortium (GenoMEL). High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006;66(20):9818–28. - PubMed
-
- Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagal W, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, Rutten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43:1018–21. - PMC - PubMed
-
- Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339(6122):959–61. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous